Ultragenyx Pharmaceutical (RARE) Total Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Total Liabilities data on file, last reported at $1.5 billion in Q1 2026.

• Total Liabilities for Q1 2026 came in at $1.5 billion, up 31.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 31.39% YoY), and the FY2025 annual result was $1.6 billion, up 29.33% from the prior year.
• Total Liabilities declined to $1.5 billion in Q1 2026 per RARE's latest filing, from $1.6 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $1.6 billion in Q4 2025 and troughed at $587.6 million in Q1 2022.
• A 5-year average of $1.2 billion and a median of $1.2 billion in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 108.6% in 2022, then dropped 3.21% in 2025.
• A 5-year view of Total Liabilities shows it stood at $1.2 billion in 2022, then rose by 1.9% to $1.2 billion in 2023, then climbed by 2.09% to $1.2 billion in 2024, then increased by 29.33% to $1.6 billion in 2025, then slipped by 4.98% to $1.5 billion in 2026.
• Business Quant data shows RARE's Total Liabilities at $1.5 billion in Q1 2026, $1.6 billion in Q4 2025, and $1.2 billion in Q3 2025.